Search Results - Tebbutt, Niall C

Refine Results
  1. 1
    Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

    Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature by Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

    Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature by Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials

    Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials by Hurwitz, Herbert I., Tebbutt, Niall C., Kabbinavar, Fairooz, Giantonio, Bruce J., Guan, Zhong-Zhen, Mitchell, Lada, Waterkamp, Daniel, Tabernero, Josep

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus

    Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus by Davey, Rachel A, Tebbutt, Niall C, Favaloro, Jenny M, O'Neal, David N, Rae, Derek, Zajac, Jeffrey D, Best, James D

    Published 2006
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

    A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction by Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines

    K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines by Yeung, Yvonne, Lau, David K., Chionh, Fiona, Tran, Hoanh, Tse, Janson W. T., Weickhardt, Andrew J., Nikfarjam, Mehrdad, Scott, Andrew M., Tebbutt, Niall C., Mariadason, John M.

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

    Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study by Lau, David K., Tay, Rebecca Y., Yeung, Yvonne H., Chionh, Fiona, Mooi, Jennifer, Murone, Carmel, Skrinos, Effie, Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*

    Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab* by Price, Timothy J, Hardingham, Jennifer E, Lee, Chee K, Townsend, Amanda R, Wrin, Joseph W, Wilson, Kate, Weickhardt, Andrew, Simes, Robert J, Murone, Carmel, Tebbutt, Niall C

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]

    The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] by Clarke, Stephen John, Burge, Matthew, Feeney, Kynan, Gibbs, Peter, Jones, Kristian, Marx, Gavin, Molloy, Mark P., Price, Timothy, Reece, William H. H., Segelov, Eva, Tebbutt, Niall C.

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

    Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial by Klein, Oliver, Kee, Damien, Nagrial, Adnan, Markman, Ben, Underhill, Craig, Michael, Michael, Jackett, Louise, Lum, Caroline, Behren, Andreas, Palmer, Jodie, Tebbutt, Niall C., Carlino, Matteo S., Cebon, Jonathan

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease

    Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease by Williams, Benjamin B., Tebbutt, Niall C., Buchert, Michael, Putoczki, Tracy L., Doggett, Karen, Bao, Shisan, Johnstone, Cameron N., Masson, Frederick, Hollande, Frederic, Burgess, Antony W., Scott, Andrew M., Ernst, Matthias, Heath, Joan K.

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

    The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors by Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial by Tebbutt, Niall C, Price, Timothy J, Ferraro, Danielle A, Wong, Nicole, Veillard, Anne-Sophie, Hall, Merryn, Sjoquist, Katrin M, Pavlakis, Nick, Strickland, Andrew, Varma, Suresh C, Cooray, Prasad, Young, Rosemary, Underhill, Craig, Shannon, Jennifer A, Ganju, Vinod, Gebski, Val

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

    DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis by Tögel, Lars, Nightingale, Rebecca, Wu, Rui, Chüeh, Anderly C., Al-Obaidi, Sheren, Luk, Ian, Dávalos-Salas, Mercedes, Chionh, Fiona, Murone, Carmel, Buchanan, Daniel D., Chatterton, Zac, Sieber, Oliver M., Arango, Diego, Tebbutt, Niall C., Williams, David, Dhillon, Amardeep S., Mariadason, John M.

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer by Cutsem, Eric Van, Eng, Cathy, Nowara, Elzbieta, Świeboda-Sadlej, Anna, Tebbutt, Niall C., Mitchell, Edith, Davidenko, Irina, Stephenson, Joe, Elez, Elena, Prenen, Hans, Deng, Hongjie, Tang, Rui, McCaffery, Ian, Oliner, Kelly S., Chen, Lisa, Gansert, Jennifer, Loh, Elwyn, Smethurst, Dominic, Tabernero, Josep

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

    Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers by Herbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel, Scott, Andrew M.

    Published 2009
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

    VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer by Chionh, Fiona, Gebski, Val, Al-Obaidi, Sheren J., Mooi, Jennifer K., Bruhn, Maressa A., Lee, Chee K., Chüeh, Anderly C., Williams, David S., Weickhardt, Andrew J., Wilson, Kate, Scott, Andrew M., Simes, John, Hardingham, Jennifer E., Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    RHOA inactivation enhances Wnt signaling and promotes colorectal cancer

    RHOA inactivation enhances Wnt signaling and promotes colorectal cancer by Rodrigues, Paulo, Macaya, Irati, Bazzocco, Sarah, Mazzolini, Rocco, Andretta, Elena, Dopeso, Higinio, Mateo-Lozano, Silvia, Bilić, Josipa, Cartón-García, Fernando, Nieto, Rocio, Suárez-López, Lucia, Afonso, Elsa, Landolfi, Stefania, Hernandez-Losa, Javier, Kobayashi, Kazuto, Cajal, Santiago Ramón y, Tabernero, Josep, Tebbutt, Niall C., Mariadason, John M., Schwartz, Simo, Arango, Diego

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou... by Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Cunningham, David

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

    Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study by Ohtsu, Atsushi, Ajani, Jaffer A., Bai, Yu-Xian, Bang, Yung-Jue, Chung, Hyun-Cheol, Pan, Hong-Ming, Sahmoud, Tarek, Shen, Lin, Yeh, Kun-Huei, Chin, Keisho, Muro, Kei, Kim, Yeul Hong, Ferry, David, Tebbutt, Niall C., Al-Batran, Salah-Eddin, Smith, Heind, Costantini, Chiara, Rizvi, Syed, Lebwohl, David, Van Cutsem, Eric

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: